Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Live Attenuated Influenza Vaccine (Fluenz™)

A Guide to its Use in the Prevention of Seasonal Influenza in Children in the EU

Abstract

Live attenuated influenza vaccine (LAIV) [Fluenz™] has a convenient intranasal route of administration. In the EU, it is indicated for the prevention of influenza disease caused by the influenza virus strains contained in the vaccine in children and adolescents aged 2 years to <18 years. The vaccine elicits a high immunogenic response, is protective against seasonal influenza infection and is associated with the development of herd immunity. LAIV is generally well tolerated, with the safety of the vaccine in the approved pediatric population generally considered to be similar to that of placebo based on clinical trials and extensive experience involving more than 39 million vaccine doses.

This is a preview of subscription content, log in to check access.

Table I
Table II
Table III
Fig. 1

References

  1. 1.

    Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011; 71 (12): 1591–622.

  2. 2.

    Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect 2012; 12(1): 36–44

  3. 3.

    Global pandemic influenza action plan to increase vaccine supply: progress report 2008 (WHO/IVB/09/05). Geneva: World Health Organization, 2009

  4. 4.

    Block SL, Reisinger KS, Hultquist M, et al. Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects. Antimicrob Agents Chemother 2007 Nov; 51 (11): 4001–8.

  5. 5.

    Fluenz® nasal spray suspension influenza vaccine (live attenuated, nasal): summary of product characteristics. London: European Medicines Agency, 2012 Feb 12

  6. 6.

    Flumist® influenza vaccine (live attenuated): intranasal spray: product monograph. Mississauga (ON): AstraZeneca Canada, 2011 Apr 12

  7. 7.

    Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998; 338 (20): 1405–12.

  8. 8.

    Bracco Neto H, Farhat CK, Tregnaghi MW, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009 May; 28 (5): 365–71.

  9. 9.

    Tam JS, Capeding MRZ, Lum LCS, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007 Jul; 26 (7): 619–28.

  10. 10.

    Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136(2): 168–75

  11. 11.

    Bernstein DI, Yan L, Treanor J, et al. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children. Pediatr Infect Dis J 2003 Jan; 22 (1): 28–34.

  12. 12.

    Nolan T, Bernstein DI, Block SL, et al. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measlesmumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 2008 Mar; 121 (3): 508–16.

  13. 13.

    Breiman RF, Brooks WA, Goswami D, et al. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine 2009 Sep 4; 27 (40): 5472–9.

  14. 14.

    Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006 Jul; 25 (7): 590–5.

  15. 15.

    Block SL, Yogev R, Hayden FG, et al. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5–49 years of age. Vaccine 2008 Sep 8; 26 (38): 4940–6.

  16. 16.

    Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181 (3): 1133–7.

  17. 17.

    Forrest BD, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008 Jul; 15 (7): 1042–53.

  18. 18.

    He X-S, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006 Dec; 80(23): 11756–66.

  19. 19.

    Sasaki S, Jaimes MC, Holmes TH, et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007 Jan; 81 (1): 215–28.

  20. 20.

    Vesikari T, Fleming DM, Aristegui JF, et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006 Dec; 118 (6): 2298–312.

  21. 21.

    Belshe RB, Gruber WC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J 2000 May; 19 (5 Suppl. 1): S66–71

  22. 22.

    Ambrose CS, Wu X, Knuf M, et al. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a recent meta-analysis of 8 randomized controlled studies. Vaccine 2012; 30 (5): 886–92.

  23. 23.

    Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007 Feb 15; 356 (7): 685–96.

  24. 24.

    Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006 Oct; 25 (10): 870–9.

  25. 25.

    Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006 Oct; 25 (10): 860–9.

  26. 26.

    Ambrose C, Levin M, Belshe R. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2011; 5 (2): 67–75.

  27. 27.

    Lum LCS, Borja-Tabora CF, Breiman RF, et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 2010; 28: 1566–74.

  28. 28.

    Davis MM, King JC, Moag L, et al. Countywide school-based influenza immunization: direct and indirect impact on student absenteeism. Pediatrics 2008 Jul; 122 (1): e260–5

  29. 29.

    Glezen WP, Gaglani MJ, Kozinetz CA, et al. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis 2010 Dec 1; 202 (11): 1626–33.

  30. 30.

    King JC, Stoddard JJ, Gaglani MJ, et al. Effectiveness of school-based influenza vaccination. N Engl J Med 2006 Dec; 355 (24): 2523–32.

  31. 31.

    Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 2000; 18 (9–10): 899–906

  32. 32.

    Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004 Feb; 23 (2): 138–44.

  33. 33.

    FluMist® intranasal live attenuated influenza vaccine, 2011–2012 formula: US prescribing information. Gaithersburg (MD): MedImmune, 2011 May

  34. 34.

    Ambrose CS, Yi T, Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2–17 years. Influenza Other Respi Viruses 2011 Nov; 5 (6): 389–97.

  35. 35.

    Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2–7 years of age. Vaccine 2008; 26 Suppl. 4; D10–6

Download references

Acknowledgments and Disclosures

This article was updated from Drugs 2011; 71 (12): 1591-622,[1] and was reviewed by E. Obarcanin, Sarajevo, Bosnia and Herzegovina.

The preparation of these articles was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Correspondence to Lesley J. Scott.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Scott, L.J., Carter, N.J. & Curran, M.P. Live Attenuated Influenza Vaccine (Fluenz™). Pediatr Drugs 14, 271–279 (2012). https://doi.org/10.2165/11207080-000000000-00000

Download citation

Keywords

  • Influenza
  • Placebo Recipient
  • Seasonal Influenza
  • Vaccine Dose
  • Oral Poliovirus Vaccine